Second‐generation FLT3 inhibitors include quizartinib (AC220; Daiichi Sankyo),15, 16 a highly selective inhibitor of FLT3‐ITD that does not inhibit FLT3‐TKD (D835 or F691) in patients,17 crenolanib besylate (CP‐868596; AROG Pharmaceuticals, LLC),18 which has FLT3‐ITD and FLT3‐TKD and PDGFR as targets, and the FLT3 and AXL inhibitor, gilteritinib (ASP2215, XOSPATA; Astellas Pharma US, Inc),19, 20 which was FDA‐approved for patients with relapsed or refractory AML with an identified FLT3 mutation, based on results of the ADMIRAL trial (NCT02421939). This evidence concerns the gene FLT3 and acute myeloid leukemia.